Alvotech, LOTTE Biologics sign US manufacturing pact

• LOTTE Biologics will make drug substance for multiple antibody biosimilars at its Syracuse site.
• The site has 40,000 liters of bioreactor capacity and completed an unannounced FDA inspection with zero observations.
• Commercial supply depends on technology transfer, manufacturing qualification and regulatory approvals.

Alvotech and LOTTE Biologics announced a long-term strategic manufacturing partnership on October 6, 2026. Under the deal, LOTTE Biologics will make drug substance for multiple antibody biosimilar products at its Syracuse facility in New York for global supply.

Alvotech, LOTTE Biologics sign US manufacturing pact

The companies said the collaboration may expand over time. They said the Syracuse site has 40,000 liters of bioreactor capacity, plus on-site process development and quality control capabilities.

Alvotech said the agreement expands its US-based manufacturing footprint and strengthens its global supply network. It said the extra capacity adds to its existing manufacturing partnerships and in-house development and manufacturing capabilities.

Management comments

Lisa Graver, chief executive of Alvotech, said the company would have sufficient capacity to meet demand for its pipeline for the next ten years. She said the partnership would bring additional manufacturing capacity in New York to support patients worldwide.

James Park, chief executive of LOTTE Biologics, said the two groups had a strong foundation for the collaboration. He said LOTTE Biologics expected to support Alvotech's growing portfolio and the supply of biologic medicines to patients worldwide.

Conditions

Commercial supply will depend on successful technology transfer, manufacturing qualification and applicable regulatory approvals.